Asterias Biotherapeutics, Inc. Common Series A (AST): Downgrade News

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Key Facts Surrounding This News Item


  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) had a POWR Rating of F (Strong Sell) coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -4.02% below its 10-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -6.98% below its 20-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -5.80% below its 50-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -1.20% below its 100-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) was -18.58% below its 200-Day Moving Average coming into today.
  • Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) had returned -31.11% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Asterias Biotherapeutics, Inc. Common Series A (AST)


Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. The company was founded in 2012 and is based in Fremont, California. View our full Asterias Biotherapeutics, Inc. Common Series A (AST - Get Rating) ticker page with ratings, news, and more.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

3 Vital Investing Strategies You Need to Know

The market and indices like SPY continue to swirl around just under 3,000. So now is a good time to retool with investment strategies that can help you carve out additional gains, even if the overall market remains range-bound. Read on for more...
: TLRY | Tilray, Inc. - Class 2  News, Ratings, and Charts

Is Tilray (TLRY) a Buy at These Levels?

Tilray was the first cannabis company to list on a major U.S. stock exchange when the company went public in July 2018.
NYSE: SPY | SPDR S&P 500 News, Ratings, and Charts

Investors: Welcome Back to the Trading Range

The stock market and indices like SPY may be stuck in a trading range a while longer as we await future phases of the China trade deal. However, there are still ways to find outperformance in the market. More details below.
: hexo | HEXO Corp. Common Shares News, Ratings, and Charts

Is HEXO Corp. (HEXO) Oversold?

HEXO seems like a classic case of a company that over-promised and will now underdeliver to its investors.
: NMRK | Newmark Group, Inc. -  News, Ratings, and Charts

9 Stocks to Get Your Heart Racing!

Newmark Group is expected to rise over 50% to its fair value target. Amazingly, that is one of the tamest stocks on this list of 9 stocks with tremendous upside potential. Read on for more.

Read More Stories


More Asterias Biotherapeutics, Inc. Common Series A (AST) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AST News
Page generated in 1.5035 seconds.